News
-
A new spin out from the University of California, Davis called InVixa announced that it has acquired the rights to UC Davis intellectual property related to delivery of statins to the lung for the treatment… Read more . . .
-
Canadian inhaler tracking and training start-up BreatheSuite has announced the completion of a $1.2 million financing round and said that it intends to use the funds for expanded distribution of its MDI add-on device in North… Read more . . .
-
Seelos Therapeutics announced that the first patients have been dosed in a Phase 2 study of its SLS-002 intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive… Read more . . .
-
Copley Scientific has announced the launch of an e-training service that allows customers to get live-streamed instruction in the use of OINDP testing equipment for in vitro testing. Both standard e-training packages and custom live-streamed… Read more . . .
-
Odyssey Group International said that it has signed a definitive agreement with Prevacus to acquire PRV-002, an intranasal therapy for the treatment of mild traumatic brain injury. As part of the deal, Prevacus CEO Jake… Read more . . .
-
Intranasal vaccine developer AuraVax Therapeutics said that the company has licensed liposomal STING agonist technology from Massachusetts General Hospital (MGH) for use as an adjuvant in vaccines against COVID-19 and other respiratory diseases. The technology… Read more . . .
-
Catalent will pay Acorda Therapeutics $80 million cash for Acorda’s manufacturing operations in Chelsea, MA, USA where the company makes Inbrija dry powder levodopa. According to Catalent, the 90,000 sq ft CGMP facility “will act… Read more . . .
-
Receptor Life Sciences (RLS) said that a pre-IND meeting with the FDA “resulted in clear guidance on the regulatory requirements” for development of the company’s RLS103 dry powder cannabidiol (CBD) for the treatment of panic… Read more . . .
-
According to Felix Biotechnology, Yale University researchers have initiated a Phase 1/2 trial of Felix’s YPT-01 nebulized phage therapy for the treatment of chronic P. aeruginosa infections in cystic fibrosis patients. YPT-01 was initially formulated at Yale… Read more . . .
-
Ovoca Bio said that its subsidiary IVIX has resubmitted a marketing application for the company’s BP-101 synthetic peptide nasal spray for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women to the Russian… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.